References
- Anacor Pharmaceuticals Inc. Kerydin (tavaborole) topical solution, 5% [Internet]. 2014 [cited 2016 Mar 8]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204427s000lbl.pdf
- LLC VPNA. Jublia (Efinaconazole) Package Insert [Internet]. 2014; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203567s000lbl.pdf
- Gupta AK, Paquet M. Management of onychomycosis in Canada in 2014. J Cutan Med Surg. 2015;19:260–273.
- Gupta AK, Studholme C. How do we measure efficacy of therapy in onychomycosis: patient, physician, and regulatory perspectives. J Dermatol Treat. 2016;27:498–504.
- Elewski BE, Aly R, Baldwin SL, et al. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: results from 2 randomized phase-III studies. J Am Acad Dermatol. 2015;73:62–69.
- Coronado D, Merchant T, Chanda S, et al. In vitro nail penetration and antifungal activity of tavaborole, a boron-based pharmaceutical. J Drugs Dermatol. . 2015;14:609–614.
- Vlahovic T, Merchant T, Chanda S, et al. In vitro nail penetration of tavaborole topical solution, 5%, through nail polish on ex vivo human fingernails. J Drugs Dermatol JDD. 2015;14:675–678.
- Vlahovic T, Coronado D, Chanda S, et al. Evaluation of the appearance of nail polish following daily treatment of ex vivo human fingernails with topical solutions of tavaborole or efinaconazole. J Drugs Dermatol. . 2016;15:89–94.
- Zeichner JA, Gold LS, Korotzer A. Penetration of (14C)-Efinaconazole topical solution, 10% does not appear to be influenced by nail polish. J Clin Aesthet Dermatol. 2014; 7:34–36.
- McAuley WJ, Jones SA, Traynor MJ, et al. An investigation of how fungal infection influences drug penetration through onychomycosis patient’s nail plates. Eur J Pharm Biopharm off J Arbeitsgemeinschaft Pharm Verfahrenstechnik EV. 2016;102:178–184.
- Gupta AK, Simpson FC. Routes of drug delivery into the nail apparatus: implications for the efficacy of topical nail solutions in onychomycosis. J Dermatol Treat. 2016;27:2–4.